



Oestrogens Regulate Proliferation in 
Colorectal Cancer via GPER and the 
Hippo signalling pathway  
 
Anastasia Arvaniti  
 
Lead supervisor: Dr Paul Alexander Foster 

















This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 






The concentration of circulating oestrogens is associated with the incidence and outcomes of 
colorectal cancer (CRC). Both the physiological and pathological effects of oestrogens are 
mediated by oestrogen receptors. This project aims to investigate the potential role of G 
protein-coupled oestrogen receptor 1 (GPER) as an oestrogen-induced mediator in CRC 
proliferation. To achieve this, colorectal adenoma and carcinoma cell lines were examined for 
protein expression of oestrogen receptors. Immunoblotting did not report ERα and ERb 
expression, although GPER was detected. Following this, the GPER-associated gene 
connective tissue growth factor (CTGF) expression was measured after 17β-estradiol (E2) 
and GPER agonist (G1) treatment. qRT-PCR results showed no significant increase in CTGF 
expression levels, 24 and 48 hours after treatment. In addition, GPER interaction with the 
Hippo pathway in CRC was examined by treating cells with E2 and G1 for 0, 15, 30 minutes, 
1, and 2 hours. Alterations in P-YAP1 expression were unclear after treatment in the cell 
lines examined. However, addition of GPER antagonist, G15, resulted in significant 
inhibition in YAP1 phosphorylation in HCT116 cells, 15 and 30 minutes of treatment. 
Consequently, our data supports that oestrogens and G1 treatment leads to increase in YAP1 
phosphorylation and nucleus-cytoplasmic shuttling via GPER stimulation. YAP1 knock-
down studies and pharmacological inhibition followed by proliferation assays established that 
this early metabolic effect translates into increased cellular proliferation. Collectively, our 
data propose a novel oestrogen-driven pro-proliferative pathway via GPER through Hippo 
pathway’s key downstream effector, YAP1, in CRC. Further studies are required to reveal the 
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1. Introduction 
 
1.1 Cancer Epidemiology   
 
For many years, cancer has remained one of the global primary causes of death following 
cardiovascular diseases. Cancer is the outcome of a vast and diverse spectrum of diseases, all 
of which are characterised by the uncontrolled growth of cells, often involving invasion into 
surrounding tissues and possibly metastasis into distant organs. The prevalence rates of 
individual cancers differ between men and women. In men, the most common cancers 
include lung, prostate and colorectal cancer, while in women the most common cancer is 
breast cancer, followed by colorectal and cervical cancer 1. 
                                      
1.1 Colorectal Cancer 
 
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in both sexes and the 
second cause of cancer-related death in Europe 2. Worldwide CRC incidence is expected to 
increase by 60% by the year 2030 and more than 2.2 million new cases are estimated to occur 
3,4. Despite CRC developing in a wide geographic area, its burden is positively influenced by 
development and westernisation. As a result CRC is most commonly seen in industrialized 
countries such as in Western Europe, North America, New Zealand and Australia 5.  
 
Hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch Syndrome, is a 
genetic condition predisposing patients to CRC. It accounts for about 3% of all CRCs and is 
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associated with the development of up to 100 colonic polyps, usually in the right colon 6. 
Familial Adenomatous Polyposis (FAP), the most common adenomatous polyposis 
syndrome, accounts for about 1% of CRC and the key feature of FAP is the presence of 
thousands of colonic polyps which usually increase with age 7. 
 
As expected, increasing age is strongly associated with CRC incidence. More specifically, the 
incidence of colorectal cancer increases dramatically above the age of 45 for both men and 
women. However, in most countries, the age-standardized incidence rates are considerably 
lower for women than for men 8. 
  
 In England from July 2006 NHS has introduced NHS Bowel Cancer Screening Programme 
(NHS BCSP). The members are offered two types of screening:  
a) A faecal occult blood (FOB) test every two years between the ages of 60-74. The 
positive samples for blood in the stools are re-tested and biopsy, or a radiological test 
is offered 9.  
b) A bowel scope screening to men and women at the age of 55 that involves 
examination of the lower part of the bowel. 
 
Considering the growth in health service capacity for early detection through screening, there 
is an increasing likelihood there will be a need for preventative therapies for CRC. The 
current known therapeutic approaches, such as surgery and anti-inflammatory drugs 10,11, 
have limited efficacy, imposing the necessity for development of new preventative or 
targeted therapies 12.  
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1.1.2 Classification and Prognosis of Colorectal cancer 
 
The treatment strategies and the prognostic prediction of patients vary according to the stage 
of CRC diagnosis13. In 1932 Cuthbert E. Dukes examined approximately 2,000 samples of 
CRC and developed the first classification system, highlighting the importance of the 
lymphatic metastasis and local tumour invasion in progression. This classification system has 
since been modified and in 1954 the Tumour, Node and Metastasis Classification (TNM) was 
proposed by Pierre Denoix. TNM is now the only classification system used for CRC 14. 
According to TNM staging colorectal tumours are classified into three categories with “T” 
(tumour) to denote the degree of invasion of the bowel wall, “N” (node) the degree of 
lymphatic node involvement, and “M” (Metastasis) the degree of metastasis (Table 1).  
 
 
Table 1: Dukes and TNM classification 5 
  Dukes TNM 
Tumour invasion confined to the mucosa A Tis, N0 
Tumour invasion limited to the submucosa, no lymph node involvement A T1, N0 
Tumour invasion limited to the submucosa, lymph node involvement C T1, N1-2 
Limited tumour invasion into the muscle layer, no lymph node involvement A T2, N0 
Limited tumour invasion into the muscle layer, lymph node involvement C T2, N1-2 
During the whole muscle layer tumour involvement, no lymph node 
involvement 
B T3, N0 
During the whole muscle layer tumour involvement, lymph node involvement C T3, N1-2 
Tumours have kept the neighbouring organs, no lymph node involvement B T4, N0 
Tumours have kept the neighbouring organs, lymph node involvement C T4, N1-2 
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1.1.3 Colorectal carcinogenesis 
 
Most CRCs develop as an outcome of accumulation of genetic and epigenetic changes in 
cancer-causing genes. These changes promote the formation of benign neoplastic 
adenomatous polyps in mucous-secreting epithelial cells. In the following stages of the 
disease the adenomatous polyps can evolve into late adenoma polyps which later progress to 
adenocarcinoma, and ultimately to invasive and metastatic colorectal carcinoma 15. This 
transition was described by the Vogelstein et al as the adenoma-carcinoma sequence (Figure 
1) 16. The pathogenesis of CRC differs according to alterations in cancer-causing genes that 
contribute to tumour initiation and progression 17,18. The Global genome sequencing of 
metastatic lesions and primary CRCs revealed hardly any metastasis-specific mutation 19. The 
cellular environment plays a pivotal role to the occurrence of genomic instability that enables 
mutations and inherited factors to develop cancer 20,21. In general, the most common genomic 
instability in CRC is chromosomal instability (CIN) which results in chromosomal 
abnormalities such as aneuploidy. Furthermore failure of the DNA repair system to detect and 
repair mismatched bases, promotes microsatellite instability (MSI) which also contributes to 
CRC along with epigenetic factors such as CpG island methylation phenotype (CIMP+) 18.    
 
In CIN and MSI the changes occur basically in two classes of genes, oncogenes and tumour 
suppressor genes22. The tumour suppressor gene Adenomatous polyposis coli (APC), the 
tumour suppressor protein p53 along with the proto-oncogene KRAS and SMAD4 are the 
most thoroughly examined genes in CRC 18. APC gene is located at chromosome 5q.22.2,  
mediates many primary cellular functions of intestinal cells including proliferation, stimulates 
the deactivation of β-catenin and restrains transcription of Wnt pathway target genes involved 
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in the cell cycle 23. P53 is located at chromosome 17p and is involved in the cell cycle, 
apoptosis and cellular senescence 24. KRAS is located at 12p12.1 and various genetic 
alterations in the gene have been associated with poor prognosis for patients on epidermal 
growth factor receptor (EGFR) inhibitors 18. SMAD4 is located at 18q, and its low expression 
has been associated with poor prognosis and limited response to 5-Fluorouracil 18.  
 
 
Figure 1: CRC initiation and progression. The adenoma-carcinoma sequence initiates with loss of the APC 
gene. Progression from adenomatous polyp to carcinoma is associated with a step-wise accumulation of genetic 
mutations in KRAS, SMAD4, loss of chromosome 18q and ultimately p53 inactivation (adapted figure) 18. 
 
Taking into consideration the male preponderance, a person’s lifetime risk of developing 
CRC is about 5% 25. Smoking, obesity, alcohol consumption and increased consumption of 
red meat and are proven risk factors for CRC initiation in 70-80% of the cases. Genetic 
predisposition accounts for 35% of the risk of CRC initiation 26. The presence of a first 
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1.4 Oestrogen and Colorectal Cancer    
 
Observational and clinical evidence has shown an association between hormones and 
mammalian neoplasia 28. The first indication of this association in colorectal cancer was 
recorded in 1969 when a groundbreaking study about cancer and marital status took place. 
The data reported that nuns, who have no disruption in their menstrual cycle due to being 
nulliparous, thus greater lifetime exposure to oestrogen, were more likely to develop CRC 29. 
The hypothesis that endogenous oestrogens act in a pro-proliferative manner in women was 
enhanced in 1980 when hormonal changes associated with pregnancy were correlated with 
lower CRC risk 30. The study of Weiss and colleagues provided further evidence in support of 
this hypothesis, finding that, on average, women with CRC had given birth to fewer children 
31. In the following years many studies demonstrated that carcinogenesis in the colon is at 
least partially mediated by endogenous oestrogens 32,33. Few studies observed no substantial 
effect or correlation between increasing parity and the risk of CRC 34,35.  
 
A big controversy came in 1994 after a case-controlled study implicating Hormone 
Replacement Therapy (HRT) (conjugated oestrogen [oestrone sulfate (E1S)] plus 
medroxyprogesterone)  as protective against CRC development in postmenopausal women 
36,37. In the following years, further human studies were warranted from the Women’s Health 
Initiative (WHI) Clinical Trial and academic research groups highlighting the positive role of 
exogenous oestrogen such as HRT or oral contraceptives, in reducing CRC risk in 
postmenopausal women  38–43. These findings suggested that oestrogens might be the key to 
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1.5 Oestrogen Biosynthesis and Metabolism Pathway 
 
Oestrogens are a diverse group of cholesterol-derived steroid hormones including oestrone 
(E1), oestriol (E3), oestetrol (E4), and the biologically active with the highest affinity for 
oestrogen receptors, 17β-oestradiol (E2). In terms of serum levels and oestrogenic activity, 
E2 is dominant between the menarche and menopause stages of life with levels highest before 
ovulation. Oestriol (E1) and oestetrol (E4) are intensively produced during pregnancy and 
when menopause is achieved E1 becomes the primary circulating oestrogen 45,46. 
 
In general, oestrogen metabolism is regulated by three key enzymes, 17β-hydroxysteroid 
dehydrogenases (17β-HSD), aromatase and steroid sulfate (STS) 47. The de novo synthesis of 
oestrogen initiates in the ovaries, adrenal gland and testis by the synthesis of androstenedione 
from cholesterol.  Androstenedione has weak androgenic activity and can be converted 
directly to E1 by aromatase or to testosterone by 17β-HSD3 and finally to estradiol by 
aromatase 48. In the additional steps of steroidogenesis 17β-HSD 1 and 2 catalyze the 
reduction of E1 to E2 and oxidation of E2 to E1 respectively. Eventually oestrogen is 
transformed to hydrophilic glucuronide or sulphate conjugates by glucuronidation and the 
sulphatase pathway, respectively. These modifications make the steroids more soluble and 
therefore easily transported in the blood. 49. 
 
 Briefly, oestrogen metabolism through the sulphatase pathway is based on steroid sulphatase 
(STS) action. STS can be found in a range of peripheral tissues allowing local synthesis of E1 
from oestrone sulphate (E1S), the most abundant oestrogen transported by the circulatory 
system to target distant organs 50. STS reduces the hydrophilic E1S to hydrophobic E1, which 
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is further reduced via 17β-HSD1 to the active oestrogen E2 28,47. E1S and all conjugated 
oestrogens are biologically inactive because of their very low affinity for the oestrogen 
receptor. However, they are of great importance taking in consideration their ability to act as 
an oestogen reservoir with twice half-life compared to E1 and E2 51 (Figure 2). 
                                                                                                                                                                       
 
 
Figure 2: Oestrogen metabolism pathway. 17β-HSD-1 and STS are responsible for the reduction of E1 to 
biologically active E2. 17β-HSD-2 and SULT1E1 oxidize E2 to E1 followed by E1 sulphation to E1S 28.  
      
Oestrogens play an important role in a plethora of physiological processes in humans and 
they have been implicated in the initiation and development of many diseases such as cancer. 
Oestrogen production and metabolism are tissue specific. In the normal colon, 17β-HSD 2 
and 4 efficiently convert E2 to E1 providing anti-proliferative effects 52,53. However, in 
colorectal cancer these enzymes are downregulated and oestrogens are shown to be locally 
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1.6 Oestrogen Receptors 
 
Oestrogens mediate their intracellular effects through their receptors (ERs) via genomic and 
non-genomic pathways. The genomic effects regulate transcription of genes associated with  
angiogenesis (VEGF), cellular adhesion (cadherins), proliferation and apoptosis by direct 
interaction with specific DNA sequences, known as oestrogen response elements (ERE) and 
transcription factors (SP1, AP1, NFkB). The non-genomic effects regulate rapid indirect gene 
transcription via pathways such as protein kinase C, calcium (Ca+), cyclic adenosine 
monophosphate (cAMP) and mitogen-activated protein kinases (MARK) 54. The term 
'membrane-initiated steroid signalling' (MISS) has been suggested as an alternative to the 
'non-genomic action’. However, this proposed term is not completely correct taking into 
consideration that non-genomic action do not always originate at the membrane 55,56. 
 
The two classic ERs, ERα and ERβ, are encoded by ESR1 and ESR2, respectively and are 
able to regulate gene expression after interacting with high affinity ligands. ERα regulates the 
oestrogenic signalling mainly in uterus, mammary gland and skeleton, whereas ERβ is 
mainly found in cells of the immune system, the prostate, the gastrointestinal tract, and the 
hypothalamus. Alternative splicing, during gene expression, produces different isoforms of 
each gene, resulting in three ERα and five ERβ isoforms, with differential tissue distribution, 
selective binding affinity, potency and efficacy for various compounds 57,54. Their mechanism 
of action can vary when it comes to ligand interaction and signaling. ERs are inactive in the 
cytoplasm where they are associated with heat shock proteins. After ligand binding, they 
undergo conformational changes that enables them to shuttle from the cytoplasm to the 
nucleus and initiate expression of the target genes, mediating the genomic effects of 
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oestrogen 55. In almost every tissue the two ERs overlap functionally 58 and specifically in 
colon ERβ is reported to diminish the transcriptional activity of ERα 54.  
 
The amount of available oestrogen has been reported to regulate the expression levels of both 
ERs 59. ERα and ERβ have different biological functions that depend on nuclear and 
cytoplasmic signaling. More specifically in colonic mucosa, although ERα has limited or no 
expression, evidence demonstrates a pro-proliferative role by regulating expression of 
proteins, such as cyclin D1, and promoting cell cycle transition. Other studies suggest that 
ERα activates the Wnt / β-catenin signalling pathway in SW480 and HCT116  CRC cell lines 
60.   
 
On the other hand, ERβ, the dominant ER isoform in CRC, is documented to be an anti-
proliferative regulator in vivo and in vitro causing cell cycle arrest via the p38/MAPK 
pathway 54,61. Furthermore, ERβ is shown to regulate TGFβ signalling pathway and decrease 
inflammation regulating IL6 54. However, evidence proposes that in CRC ERβ is 
downregulated compared to normal tissue, leading to a positive correlation between the 
receptor’s expression and the stage of the disease 62. Hence, the loss of ERβ is seen by some 
as the oestrogenic switch in CRC that leads to the loss of the anti-proliferative effects of 
oestrogen.  
 
Despite the established role of the two classic ERs, the effect of oestrogen in CRC through 
the latest discovered ER, GPER, remains unclear. GPER is a typical seven-transmembrane G 
protein-coupled receptor, widely expressed in the body, with high affinity to E2 at 
physiological concentrations 37. It emerged at the forefront of the scientific interest after 
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Filardo and colleagues revealed that it promotes rapid oestrogen-induced activation of 
ERK1/ERK2 independently of ERα and ERβ action in breast cancer cells 63. The mechanism 
was elucidated in 2004 when Maggiolini et al. using SKBR3 cells as a model system, 
determined that GPER, via ERK1/ERK2 activation, mediates an early c-Fos upregulation 64.  
The importance of GPER was elaborated after ERα positive breast tumors treated with 
hydroxytamoxifen (OHT) had intensive disease progression due to agonistic action of the 
drug to the novel receptor 65. Poola and colleagues in 2008 observed that the expression of 
GPER was downregulated in most of the breast cancer tissues in comparison to respective 
normal tissues, hypothesizing that proliferation may arise partially due to receptors loss 66. 
Furthermore, GPER has been identified as the receptor responsible for the inhibitory effect of 
oestrogens on the divergent TGFβ signalling and function 67, the oestrogen-mediator of FN 
matrix assembly and growth factor release via a Shc-dependent signaling mechanism 68 and 
the basic regulator of oestrogen induced expression and function of vascular endothelial 
growth factor (VEGF) 69 in ER-negative breast cancer cells.  
 
After the discovery that hydroxytamoxifen (OHT) is a GPER agonist, experiments were 
conducted in endometrial cancer cells, reporting increased c-Fos expression after E2 and 
OHT treatment, independently of ERs 70. In addition, GPER stimulation by tamoxifen, and 
genistein, has been reported to increase SF1 transcription, promote endometrial cell 
proliferation, and induce the SF1 target gene aromatase 71.  
 
G1, the first GPER-selective ligand and a key indicator of GPERs action, was used to identify 
the receptors role in ovarian cancer. The data showed G1 implication in ERα-dependent 
proliferation through c-Fos stimulation and ERK activation, suggesting that in ovarian cancer 
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cells GPER/EGFR  signaling is ER-dependent 72. The expression of GPER is associated with 
a poor outcome in ovarian cancer, taking into consideration the data showing that GPER 
increases Akt phosphorylation via the EGFR 73. In prostate cancer cells Chan and colleagues 
reported reduced proliferation rate after G1-induced GPER mediation of Erk1, Erk2 and p21 
74. In addition, Wei and colleagues demonstrated that activation of GPER by G1 can inhibit 
proliferation of ER negative breast cancer cells in vitro by upregulation of p53, p21 and 
downregulation of cyclin B 75. 
 
In various studies  GPER has been reported to mediate cell biological responses in 
reproductive tissue, however the receptors deletion in vivo have shown little reproductive 
anomalies compared to ERα knockouts 76. GPER localization varies between tissues and 
evidence proposes a possible membrane-cytoplasmic shuttling of the receptor 77. It is reported 
to be located on the plasma membrane as a typical ER in uterine, myometrium and renal 
epithelia and intracellularly, possible in the endoplasmic reticulum, in normal and cancerous 
epithelia in ovaries and endometrium78. The intracellular localisation can be associated with 
slow release from the endoplasmic reticulum during receptor biosynthesis as well as receptor 
downmodulation during reuptake 79.  
 
According to studies in samples from patients with reproductive tumours,  GPER action is 
independent from the other ERs 78 and it is reported to mediate various target genes and have 
a broad of biological and pathological functions 80. Gene expression profiling of GPER 
signaling in breast cancer has shown mediation of various genes, such as c-Fos, cyclins A, D1 
and E, VEGF and CTGF 81. CTGF, the higher GPER-induced gene, is a member of the CCN 
family of matricellular proteins 82, is implicated in cell division, apoptosis, adhesion, motility, 
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angiogenesis 83, tumor development 82 and along with the Hippo pathway constitute the two 
basic proposed downstream signaling targets of GPER in cancer.    
 
1.7 Hippo signaling pathway 
 
As a highly conserved pathway in mammals and a basic regulator of organ size and tissue 
regeneration, the Hippo pathway has been attracting considerable attention in the last decade 
(Yu et al. 2015). The pathway’s basic mediators are demonstrated to be the yes-associated 
protein 1 (YAP1) and its transcriptional co-activator PDZ-binding motif (TAZ). These co-
activators compete with the transcription co-factor vestigial-like protein 4 (VGLL4) for 
binding with the TEAD family transcription factors (TEAD1–4) and promote target gene 
expression 85,86. YAP/TAZ activity is regulated by a core kinase cascade, mammalian sterile 
like kinase 1/2 (MST1/2). MST1/2 phosphorylates Mob kinase activator 1A/B (MOB1) and 
Salvador protein (SAV1) and activates protein kinase, large tumor suppressor kinase 1/2 
(LATS1/2) which directly phosphorylates YAP/TAZ. Depending on the position of the 
phosphorylation site, a 14-3-3 binding region is generated, allowing YAP1 sequestration in 
the cytoplasm. Alternatively, ubiquitin is activated, leading to proteasomal degradation of 
YAP1 (Figure 3) 84.  
 
The upstream regulators of Hippo pathway remain poorly understood. Up to date, tumor 
suppressor homolog 4 (FAT4), neurofibromin 2 (NF2) and Bona fide human tumor 
suppressor (KIBRA) have been suggested as upstream components. FAT4 interacts with 
atypical cadherin, Dachsous (Ds) and regulates membrane’s organization with a low affinity 
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to the pathway’s progression. NF2 and KIBRA, sequesters LATS1/2 to the plasma membrane 




Figure 3: Hippo pathway: Main regulators and signalling. (Left) Hippo signalling is on, YAP/TAZ are 
phosphorylated on multiple sites and remain in the cytoplasm bind to 14-3-3 or face protein degradation by the 
ubiquitin system. (Right) Hippo signalling is off, YAP/TAZ enter the nucleus, interact with TEAD1-4 and 
activate target genes. 
 
Evidence proposes the existence of an additional Hippo-like signaling pathway where 
MST1/2 is not necessary for LATS1/2 activation 88 and where YAP/TAZ are phosphorylated 
by other kinases 89. Mitogen-activated protein 4 kinase (MAP4K) family and 
Serine/threonine-protein kinase (STE20) family members have been reported to facilitate 
LATS1/2 activity as a response to tissue-specific upstream signals 84,90,91. YAP/TAZ have 
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been demonstrated to be deactivated by cyclin-dependent kinase 1 (CDK1), Jun N-terminal 
kinases (JNK), homeodomain-interacting protein kinases (HIPK), and Src family tyrosine 
kinases 89.  
 
Literature reports that the Hippo pathway is dysregulated in many human neoplasms, 
including CRC, playing a paramount role in cancer development and progression. YAP/TAZ 
co-activators in their non-phosphorylated form increase proliferation  92,  YAP1 as  an 
oncogene  and TAZ as a mediator of the epithelial-mesenchymal transition (EMT) and the cell 
migration-invasion 93. The evidence suggests a synergistic action between YAP1 and TAZ 
depending on the common TEAD-mediated transcription pathway but also an independent 
less efficient anti-apoptotic action though different mechanisms 94. The mechanisms 
underlying these effects have not been fully elucidated. 
 
Research has been devoted to identifying the unknown upstream moderators as the key to the 
pathways proliferative action, with G-protein-coupled receptors repeatedly noted as 
mediators through Rho GTPase and cytoskeleton remodelling 95,96. In breast cancer, 
published data have demonstrated that oestrogens can activate GPER, which forward controls 
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1.8 Aims 
 
There is evidence in the literature that suggests an association between oestrogen and 
colorectal cancer. Epidemiological studies of the Women's Health Initiative (WHI) indicate 
exogenous HRT as protective against CRC development. However, how oestrogens impact 
CRC once it has developed remains poorly understood. 
 
A recent paper by our lab revealed some important information about oestrogens role in 
CRC. Our data suggest, CRC cell lines (Caco2, HCT116 and HT29) express high amount of 
steroid sulfatase (STS), and are able, through OATP4A1 transporter, to internalise E1S and 
E2S and hydrolyse them to their active forms 49. Moreover, our data suggest that the 
increased STS activity is mediated by oestrogenic GPER-stimulation and is associated with 
increased tumour burden in cell and animal models 37. Therefore, the aim of this project was 
to verify GPER’s pro-proliferative role and investigate the possible downstream mechanism 
of action of GPER stimulation. Furthermore, the project will examine whether E2-GPER 
interaction induces CTGF, a known regulator of GPER action, and/or alters the Hippo 
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2. Methods and Materials 
 
2.1 Health and Safety 
 
Good Laboratory Practice was employed; a lab coat and gloves were worn when performing 
all the procedures. Sterile conditions were utilised for the prevention of contamination of cell 
cultures and RT-PCR experiments. To secure aseptic environment, separate coats were used 
for cell culture and other labs, gloves were frequently changed and sanitised with 70% 
ethanol, the reagents were always kept up to date and the labs where cleaned fortnightly. 
 
2.2 Cell culture techniques 
 
2.2.1 Human colon cancer cell lines 
 
HCT116, HT29, CACO2 (Table 2) are immortalised, adherent, epithelial colon cancer cell 
lines kindly provided by Professor C. McCabe (University of Birmingham) and Professor C. 
Tselepis (University of Birmingham).  Culture media  McCoy’s 5A Medium (Modified) 
(Sigma-Aldrich,UK)  and  Minimum Essential Medium (MEM) (Sigma-Aldrich,UK) were 
used with 2.0 mM  L-glutamine, sodium bicarbonate, 10% v/v heat inactivated fetal bovine 
serum (FBS) (Thermofischer Scientific,UK), 100 U/ml and 100 μg/ml 
penicillin/streptomycin (Thermofischer Scientific, UK). Cells were grown at 37°C in 5% CO2 
with saturating humidity and split after reaching 90% confluency. During splitting, growth 
medium was aspirated, cells were washed with phosphate buffered saline (PBS) (Thermo 
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Scientific, UK) and detached by TrypLE™ Express Enzyme (1X) (Thermofischer Scientific, 
UK). Cells were resuspended into T-75 flasks (Sigma-Aldrich, UK) containing fresh, pre-
warmed medium at required density. The cells were microscopically examined for degree of 
confluence, bacterial or fungal contaminants and the growth medium was renewed 2 – 3 
times per week.  
 
Table 2: Description of cell lines 







MEM Monolayer  1:3 




McCoy’s 5A Multilayer  1:10 
AA/C1 Colonic adenoma DMEM  Multilayer 1:3 
RG/C2 Colonic adenoma DMEM Multilayer 1:5 
 
2.2.2 Human colonic adenoma cell lines 
 
Two human non-tumorigenic adenoma cell lines were part of this study; AA/C1 and RG/C2 
(Table 2). These cells were kindly provided by Professor C. Paraskeva, CRC Laboratories, 
University of Bristol, UK. The cell lines were cultured in Dulbecco’s Modified Eagle’s 
Medium - high glucose (DMEM) (Sigma-Aldrich, UK), with 4500 mg/L glucose, 2.0 mM  L-
glutamine, sodium bicarbonate, without sodium pyruvate, containing 20% v/v heat 
inactivated fetal bovine serum (FBS) (Thermofischer Scientific, UK), 0.2 Units ml−1 insulin 
(Sigma-Aldrich, UK), 1 μg ml−1 hydrocortisone (Sigma-Aldrich, UK) and maintained at 37°C 
in humidified conditions with 5% CO2. 
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2.2.3 Oestrogen starvation 
 
Studies influenced by steroid hormones, such as oestrogen action, were carried out in cells 
grown in media with very low concentration of steroids. Components with oestrogenic action 
such as Phenol red were excluded and FBS was mandatory stripped of hormones with 
charcoal without loss of necessary serum nutrients. During the experiments the cells were 
grown in Phenol-red free Hyclone McCoy’s 5A modified medium with L-glutamine (Thermo 
Scientific, USA) and 10% HyClone TM Charcoal/Dextran Treated Fetal Bovine Serum (GE 
Healthcare, US). The duration of oestrogen starvation varied for 24-96 hours according to 
experiments (Table 3).  No antibiotics were used. 
 
Table 3: Experiments conditions 
 
Duration 
Experiment Starvation Treatment 
Starting Cell 
density Treatment solutions 
CTGF 
regulation 24 h 24 ,48 h 
250.000/well                
(6 well plate) E2 , G1 (100nM) 
YAP1 
regulation 24 h 0, 15, 30 min 1, 2 h 
250.000/well                
(6 well plate) E2 , G1 (100nM) 
P-YAP1 
regulation 24 h 15, 30 min 
250.000/well   
(6 well plate) 




assay 96 h 48 h 
500/well                  
(96 well plate) 
E2 , G1 (100nM), G15 
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2.2.4 Treatment solutions 
 
Oestradiol (E2) (Figure 4) was maintained as lyophilized powder (Sigma-Aldrich, USA) 
covered with foil for minimum light degradation. A 10mM stock solution was prepared in 
ethanol prior to experiments and stored in -20°C for up to 1 month. G1 and G15 (Figure 4) 
(Tocris, UK) were also supplied in powder form and immediately after arrival were dissolved in 
DMSO and stored in -20°C as 10mM stock. All the E2 stock solutions were prepared in glass 
vials to minimise interaction with plastic and loss of oestrogens during storage. Sterile 
Eppendorf tubes were used for G1 and G15 stocks and for all treatment solutions for immediate 
use.  
 
                               
 
        
Figure 4: Molecular structures of 17β-oestradiol, GPER specific agonist G1 and antagonist G15 
 
 
For treatments in 6 and 96 well plates the concentrations of all substrates were calculated on 
basis of 1mL and 100 μl per well respectively.  For the dilution the formula CinitialVinitial =CfinalVfinal 
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was used and solutions were always mixed with vortex mixer to ensure homogeneous 
distribution prior use. 
 
2.3 Gene expression Analysis 
 
2.3.1 mRNA isolation and quantification 
 
mRNA extraction was performed with the RNeasy Mini kit (Qiagen, UK). Following 
treatment with oestrogens, the media was removed and cells were scraped while incubated 
with RLT lysis buffer. Lysates were collected and transferred to labelled 1.5 ml tubes. An 
equal volume of 70% ethanol was added to each sample, and after homogenization with 
needle and syringe they were transferred to an RNeasy Mini spin column and centrifuged. 
Samples were washed once with 700μl RWI buffer and twice with 500 μl RPE buffer. RNA 
was eluted in a RNA free 1.5ml tube by pipetting 30 μl of RNAse-free water directly onto the 
spin column membrane and centrifuging for 1 min at >8000 x g. A NanoDrop 
spectrophotometer (Labtech International, UK) was used to quantify mRNA concentration by 
absorbance measurement at 260 nm. The 260/280 ratio was used to verify the samples purity; 
hence samples with ratios above 2 were only accepted. 
 
2.3.2 Reverse Transcription 
 
cDNA was generated from mRNA with the Tetro cDNA synthesis Kit (Bioline, Uk). For all 
samples, 1000ng of mRNA were used. All solutions and mRNA samples were vortexed and 
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centrifuged briefly before use. The priming premix was prepared on ice in RNase-free 
reaction tube and was mixed gently by pipetting before being aliquoted to tubes with the 
corresponding mRNA amount and DEPC-treated water (Table 4). The samples were 
incubated at 45 °C for 30 min and the reaction was terminated at 85 °C for 5 min. For long 
term storage the cDNA was kept at -20 °C. 
 
Table 4: Quantities used to prepare the cDNA synthesis reaction per sample. 
Total mRNA  nµl 
Oligo (dT)18 1 µl 
10mM dNTP mix 1 µl 
5x RT Buffer 4 µl 
RiboSafe Rnase Inhibitor 1 µl 
Tetro Reverse Transcriptase (200u/ul) 1 µl 
DEPC-treated water to 20 µl 
 
 
2.3.3 Real-Time Quantitative PCR 
 
To assay induction of CTGF mRNA expression, serum-starved cells received E2 and G1 
treatment for 24 and 48 h at a concentration of 100 nM. qRT-PCR was performed to measure 
the mRNA levels of target genes (Table 5, Figure 5). 
 
Table 5: qRT-PCR Master Mix preparation per 1ul of cDNA 
 
TaqMan Gene Expression Master mix (2x)        5 µl 
Probe for Gene of Interest  0.5 µl 
RPLPO Primers/probe      0.5 µl 
                                            Nuclease-free water                                                3 µl 
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Figure 5: PCR program 
 
 
Taqman assay and dual-labelled fluorogenic hybridization probes were used (CTGF, 
Hs01026927_g1, Thermo Scientific™,UK). Large Ribosomal Protein gene (RPLPO, 
4310879E, Thermo Scientific™,UK) was used as housekeeping-reference gene for data 
normalisation (Figure 6). Threshold cycle number (Ct) using the equation 1000*2^-ΔCt was 
converted into arbitrary units of transcript molecules. Real Time PCR 7500 software was 
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Figure 6: qRT-PCR mechanism. A)Target gene B)Denaturation of the template at 95 degrees. C)Primer in 
black and dual-labeled fluorogenic hybridization probe in red bind on DNA and extension face of the PCR 
starts. The probes are attached to a fluorescent dye serving as a Reporter (R, FAM or VIC) and a Quencher 
(Q,TAMRA) which absorbers emission when close to the reporter. D)The method exploits the 5' endonuclease 
activity of Taq DNA polymerase to expand the primers and the exonuclease activity of the enzyme to cleave the 
oligonucleotide probe during PCR, generating a detectable signal monitored in real time.  
 
2.4 Determination of protein concentration 
 
Protein quantification was performed with Pierce® Bicinchoninic Acid (BCA) Protein Assay 
Kit. Serial dilutions (Table 6), of stock solution bovine serum albumin (BSA) were used to 
construct a standard curve. The BCA Reagent consists of 98% Reagent A and 2% Reagent B 
(50:1 dilution of A to B). Protein lysate and BSA standards were placed in duplicates in 96-
well plate and diluted in a ratio 1:20 using the BCA Reagent. After 30 minute incubation at 
37 °C, the absorbance of the standard and samples was measured at 562 nm. The mean 
absorbance measurement of the samples was calculated and the mean value of the blank 
standard was subtracted from the mean absorbance of all the other samples. This final 
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absorbance of each BSA standard with its matched concentration in μg/mL was used to 
construct a standard curve. The chart was used only when the R-Squared value was above 
95% and the concentration of the samples was calculated according to the equation “y = mx + 
c”, where “y” stands for absorbance at 562 nm and “x” for protein amount. 
 
Table 6: Preparation of diluted bovine serum albumin (BSA) standards 
Diluent Volume Ripa Buffer (µl) BSA Source and Volume (µl) Concentration (µl /ml) 
0 200 of stock (2mg/ml) 2,000 
66 200 of stock (2mg/ml) 1,500 
100 100 of vial A 1,000 
100 100 of vial B 750 
100 100 of vial C 500 
100 100 of vial E 250 
100 100 of vial F 125 
100 0 0 
 
 
2.5 Western Blotting 
 
2.5.1 Polyacrylamide Gel Electrophoresis 
 
Quantity of cell lysate containing 25 µg of protein was diluted with Laemmli Buffer 2x (Bio-
Rad, UK) and boiled at 100 °C for 5 minutes. The samples were loaded into wells in Tris-
glycine SDS-polyacrylamide 10% gel (Table 7, 8), polymerised in a gel caster consisted of a 
short glass plate (Bio-Rad, UK), a 1.5 mm spacer plate (Bio-Rad, UK), and a 1.5 mm loading 
comb (Bio-Rad, UK) with 8 µl of Precision Plus Protein Dual Color Standards (Bio-Rad, 
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UK). The gel was placed into a Mini-PROTEAN® 3 Cell Assembly apparatus (Bio-Rad, 
UK) containing 10X Tris/glycine/SDS running buffer (Bio-Rad, UK) diluted ten times with 
distilled water. The gel at first was run at 70 volts (V) for 20 minutes and after the proteins 
enter the resolving gel the voltage was raised to 140 V for 1 hour and half.  
 
Table 7: Resolving Gel preparation quantities  
Resolving  Gel 
Protogel 30% 3.33 ml 6.66 ml 9.99 ml 13.32 ml 
Resolving Buffer 2.5 ml 5 ml 7.5 ml 10 ml 
Deionised water 4.17 ml 8.34 ml 12.51 ml 16.68 ml 
APS 10% 100 µl 200 µl 300 µl 400 µl 
TEMED 10 µl 20 µl 30 µl 40 µl 
 
 
Table 8: Stacking Gel preparation quantities 
Stacking  Gel 
Protogel 30% 0.325 ml 0.65 ml 0.975 ml 1.3 ml 
Resolving Buffer 0.625 ml 1.25 ml 1.875 ml 2.5 ml 
Deionised water 1.525 ml 3.05 ml 4.575 ml 6.1 ml 
APS 10% 12.5 µl 25 µl 37.5 µl 50 µl 
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2.5.2 Immunoblotting transfer 
 
The gel was equilibrated in Transfer Buffer for 15 minutes. The proteins were transferred to 
Nitrocellulose membrane by wet transfer using protein blotting cassette (Figure 7). The 
cassette was placed in the transfer apparatus with 1x transfer buffer (Appendix: Table 10). 
The black side of the cassette was facing the black side of the apparatus. The transfer process 
ran for 1 hour and a half at 360 mA at room temperature. 
 
 
Figure 7: Structure of blotting cassette 
 
2.5.3 Antibody Staining and Film Exposure 
 
To prevent the non-specific binding, the membrane was soaked in blocking solution for 1 
hour to overnight. After blocking, the membrane was rinsed 3 times for 5 minutes with PBS-
T or TBS-T depending on the used primary antibody. The membrane was incubated with a 
corresponding antibody (primary) for the protein of interest followed by a secondary antibody 
that binds to the primary. The primary antibodies and their working dilutions are shown in 
Table 9. The secondary antibody conjugated to Horse Radish Peroxidase (HRP) was then 
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activated by ECL (RPN2106, GE Healthcare Life science) that was applied to the membrane. 
The emitted light was captured on X-ray film. The membranes were stripped to remove the 
antibodies and incubated with β–actin antibody (A5441, ThermoFisher Scientific), a 
‘housekeeping’ gene to determine the same amount of protein has been loaded for each 
sample. 
 
Table 9: Concentrations of the primary and secondary antibodies 
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2.6 Immunocytochemistry: Cell Fixation, Permeabilisation and Staining 
 
Glass coverslips were sterilized in 90% ethanol and coated with Poly-l-lysine (P4832, Sigma-
Aldrich) on 6-well tissue culture plates (CLS3506, Sigma-Aldrich) for 10 minutes in a sterile 
tissue culture hood. Cell suspension was added over each coverslip to a finally density of 
200,000-350,000 cells per well. After 24 hours incubation, the medium was removed and the 
cover-slips were rinsed with PBS twice (1 ml per well) at room temperature. The cells were 
fixed with 4% (w/v) paraformaldehyde in PBS for 15 minutes, quenched with 1ml of 0.1 M 
glycine-PBS for 5 min and permeabilized with 1ml 0.1% Triton-X-100-PBS for 5 min at 
room temperature. The coverslips were incubated in diluted primary antibody (1:100 in 5% 
BSA-PBST, YAP1) for 1 hr 30 mins and then in secondary Alexa® Fluor 488 antibody 
(1:100, anti-rabbit) for 1hr in the dark at room temperature. A control was prepared for every 
antibody without adding the primary antibody. Any fluorescence that was seen was due to the 
secondary antibody binding non-specifically to the sample. To stain the nuclei, Hoechst 
33342 fixed cell stain was used for 10 min in the same conditions. For the coverslip 
mounting, Mowiol mounting medium (81381, Sigma-Aldrich) was used and the slides were 
left to dry overnight at room temperature protected from light. The next day, they were 
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transferred to a fridge or in -20 °C freezer for long term storage. Imaging was done using a 




2.7.1 Cell counting  
 
Cells grown in stripped media for 72h were trypsinised. The suspension was centrifuged at 
1500 rpm for 5min, the supernatant was aspirated to remove the trypsin and the cell pellet 
was washed with PBS. After centrifuged again the cells were re-suspended in stripped media 
and 10 μl of the suspension were visually counted with a disposable haemocytometer. The 
average number of cells (from 3 boxes) was multiplied by 10 times to give the final 
concentration. The initial seeding density for the cells treated had been previously optimised 
by members of the lab at 500 cells per 100μl per well, subsequently ~500.000 cells in a 96 
well plate. The fraction of cell number per plate over the concentration was calculated and 10 
ml of suspended cells were prepared accordingly.       
 
2.7.2 BrdU proliferation assay  
 
Proliferation activity was measured using the BrdU (Colorimetric) kit (Roche, Germany). 
This rapid non-radioactive assay is based in the incorporation of bromodeoxyuridine (BrdU), 
a synthetic nucleoside analogue of thymidine, into the replicating DNA, localisation of 
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labelled cells using monoclonal antibody and measurement of the fluorescent immune 
complex by an ELISA multi-label reader (Wallac, Victor3 1420) at wavelength of 405nM 97.  
 
Proliferation assays were carried out in flat-bottomed 96-well plates, seeded as described, 
following the manufacturer’s protocol. A total of 6-well repeats were carried out for all 
assays. After incubation in the 96 well plate for 24 hours, the media was carefully aspirated 
and 100µL of warmed treatment solution was added into each well using a single channel 
pipette. The cells were retreated the next day and after 24 h incubation BrdU labelling 
solution was added. Four hours later the cells were fixed for 30 minutes and immersed in 
anti-BrdU solution. The antibody solution was removed after 90 minutes and after 3 washes 
with PBS an immune complex detection reagent was added. The plate was placed on a rocker 
for 25 minutes before being read by the ELISA multi-label reader. The averages of the well 
repeats was used to find a mean absorption value and the final mean absorption was 
calculated after subtracting from the average absorption the average absorption values of 
blanks (media without cells). Optimization of the results was applied with values greater than 
two times the SEM to be excluded prior averaging. 
 
2.6 YAP1 SiRNA silencing 
 
Knockdown of YAP1 was carried out with small interfering RNA (siRNA). RNA silencing 
refers to negative regulation of gene expression triggered by sequence-specific double-
stranded RNA (siRNA) that operate within the RNA interference (RNAi) pathway by 
activating a degradation process 98,99  
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Silencing was carried out on colorectal carcinoma HCT116 cells while optimising the 
technique. YAP1 siRNA (Dharmacon, UK) was delivered into the cells using DharmaFECT 4 
Transfection Reagent. DharmaFECT 4 Transfection reagent forms liposomes in serum free 
media (Opti-Mem, Life Technologies) which entraps the siRNA within. Cells were incubated 
in 6-well plates at a density of 200.000 cells per well in dsFBS media. 24 hours later a 
treatment solution of 25 nM of siRNA and 2 µl of DharmaFECT 4 Transfection Reagent was 
made up in 2 mls per well of Opti-Mem as protocol describes. The dsFBS media was 
carefully aspirated and replaced with 2mLs of the siRNA solution and incubated in a 
humidified incubator at 37°C, 5% CO2. After 24 hours, the treatment solution was aspirated 
and replaced with dsFBS stripped media. Opti-Mem -only control were carried out to ensure 
they were not confounding factors. Silencing was confirmed by RT PCR and western blot, 
from RNA and protein extracted 24, 48, 72 and 96 hours post transfection. 
 
2.7 Data analysis 
 
The results were analysed using GraphPad Prism software. All the values were expressed as 
mean ± S.E.M. For the statistics unpaired 2-tailed Student’s t test was used and p value <0.05 
was taken as the level of significance. The western blots were analysed with IMAGEJ 
software. In detail the western blots were scanned and saved as pictures. The files were open 
with IMAGEJ and the mean intensity of each couple of bands P-YAP1 and YAP1 were 
measured using Analyse -> Gels -> Select first line (P-YAP1) -> Select second line (YAP1). 
The values were exported to excel and the ratio of P-YAP1/YAP1 was calculated to express 
the amount of YAP1 that is phosphorylated in every time point.  
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3. Results 
 
3.1 GPER is expressed in colon cancer and colon adenoma cells 
 
Oestrogens affect the incidence and outcomes of colorectal cancer (CRC) 28. Previous 
projects in the lab have shown that steroid sulphatase (STS), the enzyme that converts 
conjugated oestrogens to their active forms 50, is significantly upregulated in human CRC 
tissue leading to increased availability of active oestrogen. Furthermore, the increase in STS 
activity substantiated greater CRC tumour burden in mouse models 37. However, the role of 
oestrogen is regulated apart from their amount and the presence or absence of oestrogen 
receptors that mediate their action. Thus, we first determined the oestrogen receptor status of 
our CRC cell lines.  
 
qRT-PCR showed very low expression of the oestrogen receptors genes with general AU<0.8 
(Figure 8A,B,C). Immunoblotting showed GPER as the only receptor expressed in all the cell 
lines examined. The colon cancer cell lines HCT116, HT29 and colon adenoma cell line 
RG/C2 assembled only this receptor. JEG3, Caco2 and Colo205 exhibited some long isoform 
ERα immunoreactivity. MCF7 were used as control for ERα and ERβ expression (Figure 
8D). Immunoblotting for ERα showed no band for MCF7 at 66kDa. However, bands 
appeared at approximately 48kDa and 36kDa (Appendix: Figure 21) verifying that other 
isoforms of ERα are present (ER46 and ER36, respectively). 
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Figure 8: GPER is the dominant oestrogen receptor in CRC cell lines. A-C) Mean (± SEM) total relative ESR1 
(A), ESR2 (B) and GPER (C) expression in HCT116, HT29, CACO2 and RG/C2 cells obtained from individual 
passages (n = 3), grown in full media withought treatment. D) Immunodetection of ERα (66 kDa), ERβ (59 
kDa), GPER (38 kDa) in human colon adenoma and adenocarcinoma cell lines. Cell lysates from  AA/C1, 
RG/C2, CACO2, HT29 and HCT116 cells were resolved by 10% SDS–PAGE with B-actin as the loading 
control.  
 
3.2 Oestrogenic stimulation of GPER increased proliferation in CRC cell lines 
 
The absence of ERα/ERβ in combination with GPER’s expression led us to focus on the role 
of this receptor in CRC. To assess the role of GPER in CRC we employed BrdU proliferation 
assays. HCT116 cells were used as the most suitable as they did not express ERα and ERβ. 
Cells grown in stripped media for 24 hours were treated with E2, or G1, a GPER specific 
agonist, for 48 hours. In the same experiments cells were also treated with E2 or G1 with the 
addition of G15, a GPER antagonist (Figure 9). 
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Figure 9: GPER stimulation with E2 and G1 increased proliferation in HCT116 cells. The effected was 
inhibited by GPER antagonist G15. HCT116 cells were treated with E2 (100nM) and G1 (100nM) for 48 hours 
with and without the addition of G15 (1 uM). Viable cells were analyzed using BrdU assay, whose results are 
expressed as absortion in 405nm. All conditions are normalised to the media with charcoal stripped FBS (sFBS) 
without cells (blank). 2-tailed Student’s t test showed significant difference among E2 and G1 treatments after 
G15 addition ** p < 0.01, *** p < 0.001. (n = 6, ± SEM). 
 
The results show a trend towards increase in the proliferation rate of HCT116 cells after G1 
and E2 treatment. Furthermore, the proliferation rate of the cells is significantly decreased 
after the addition of G15, at approximately 35%, suggesting GPER acts pro-proliferative in 
CRC.  
 
3.3 Mechanism of GPER signalling 
 
3.3.1 CTGF is not oestrogen-induced in CRC via GPER 
 
Previous data in breast cancer have shown GPER to increase proliferation through connective 
tissue growth factor (CTGF) 81. Thus, we next examined CTGF expression after E2 and G1 
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treatment in CRC cell lines. Before examining the possible upregulation of CTGF through 
GPER, CTGF expression was confirmed (Appendix: Figure 22). The cells treated with E2 
and G1 for these experiments were HCT116 and HT29. CACO2 cells were also examined to 
investigate whether ERα presence would lead to any differences in the result.  The arbitrary 
expression of CTGF mRNA in the cells relative to housekeeping gene RPLPO showed no 
significant difference or trend between the treatments and the control (Figure 10).  
 
 
Figure 10: CTGF mediation is independent of GPER oestrogenic stimulation. Mean (± SEM) total relative 
CTGF expression of CACO2 (A,B), HCT116 (C,D) and HT29 (E,F) cells obtained from individual passages (n 
= 3) after consecutive treatments with oestrogens (E2) and G1, in stripped media after 24 (A,C,D) and 48 
(B,D,F) hour with normal media as control. 2-tailed Student’s t test showed no significant difference among 
treatments.  
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3.3.2 Oestrogen increased P-YAP1 expression in HCT116 but not in colon adenoma cells  
 
GPER is suggested to mediate its effects via the Hippo Pathway in breast cancer 96. To 
investigate whether YAP1 is oestrogen induced through GPER in CRC, HT29 (figure 11), 
RG/C2 (Figure 12) and HCT116 (Figure 13) cells were treated with E2 and G1 for up to 2 
hours. Cell lysates were extracted and used for immunoblotting (Figure 11A, 12A, 13A). To 
furtherly examine possible mediation of the Hippo Pathway through the GPER, we repeated 
the experiment with the addition of G15. Proteins were extracted 15 and 30 minutes after 
treatment. P-YAP1 and total YAP1 was immunodetected with β-actin as loading control 
(Figure 11B, 12B, 13B) and the ratio of P-YAP1 to the total YAP1 was calculated with the 
use of ImageJ (Figure 11C, 12C, 13C). In all the cell lines, no trend in the alterations of P-
YAP1 expression was observed following E2 and G1 treatment in the 2-hour period. 
However, in HCT116 cells inhibition of GPER action with G15 led to a decrease in p-YAP1, 
15 and 30 min after treatment (Figure 13C).  
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Figure 11: YAP1 is not regulated by GPER in HT29 cells. A) Cell lysates from HT29 cells were resolved by 
10% SDS–PAGE with B-actin as the loading control after 0, 15, 30 minutes, 1 and 2 hours of E2 and G1 
treatment. B) Cell lysates from HT29 cells were resolved by 10% SDS–PAGE with B-actin as the loading 
control after 15 and 30 minutes of E2 and G1 treatment with the addition or absence of G15. C) The ratio of the 
relative intensity of P-YAP1 to YAP1 measured by ImageJ. 2-tailed Student’s t test showed no significantly 
different among treatments.            
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Figure 12: YAP1 is not regulated by GPER in RG/C2 adenoma cells. A) Cell lysates from RG/C2 cells were 
resolved by 10% SDS–PAGE with B-actin as the loading control after 0, 15, 30 minutes, 1 and 2 hours of E2 
and G1 treatment. B) Cell lysates from RG/C2 cells were resolved by 10% SDS–PAGE with B-actin as the 
loading control after 15 and 30 minutes of E2 and G1 treatment with the addition or absence of G15. C) The 
ratio of the relative intensity of P-YAP1 to YAP1 measured by ImageJ. 2-tailed Student’s t test showed no 
significantly different among treatments.  
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Figure 13: YAP1 is regulated by GPER in HCT116 cells. A) Cell lysates from HCT116 cells were resolved by 
10% SDS–PAGE with B-actin as the loading control after 0, 15, 30 minutes, 1 and 2 hours of E2 and G1 
treatment. B) Cell lysates from HCT116 cells were resolved by 10% SDS–PAGE with B-actin as the loading 
control after 15 and 30 minutes of E2 and G1 treatment with the addition or absence of G15. C) The ratio of the 
relative intensity of P-YAP1 to YAP1 measured by ImageJ. 2-tailed Student’s t test showed significantly 
different among treatments after G15 addition, 30 minutes after treatment.  * p < 0.05, ** p < 0.01.  
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Immunofluorescence was also used to verify YAP1’s mediation through GPER after G1 
treatment in HCT116 cells (Figure 14). The use of total YAP1 antibody revealed that in the 
untreated HCT116 cells (control) YAP1 is mainly located inside the nucleus (YAP1 form). 
G1 treatment led to rapid translocation of the protein from the nucleus to the cytoplasm (P-
YAP1 form) and inhibition of GPER action with G15, blocked this effect.  
 
     
 
 
Figure 14: Immunocytochemistry of total YAP1 (green) in human cancer colon cell line HCT116. The Nuclear 
DNA labelling (blue) was done with Hoechst 33342. YAP1 was detected both in the nuclei and the cytoplasm 
following 30 min of G1 treatment. After inhibiting the action of GPER with G15, the protein was localized 
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To confirm GPER stimulation increases P-YAP1 expression in HCT116 cells we repeat the 
experimental set up (E2 and G1 treatment with extractions after 0, 15, 30 minutes, 1 and 2 
hours) with cells starved of oestrogen for 48 hours (Figure 15). The results showed a trend in 
both E2 and G1 treatment toward increase in P-YAP1 expression immediately after treatment 
compare to untreated control.  
 
Figure 15: Immunodetection of P-YAP1 and YAP1 (75 kDA). Cell lysates from HCT116 cells, starved for 48 
hours, were resolved by 10% SDS–PAGE with B-actin  as the loading control.  E2  and G1 caused an increase 
in P-YAP1 for 30 minutes after treatment and the response was decreased after 1 hour. 
 
3.3.3 Verteporfin inhibits the proliferative effect of GPER in HCT116 cells 
 
To investigate the function of YAP1 in GPER-induced tumour cell proliferation we employed 
a pharmacological inhibition of YAP1, Verteporfin. Various lower concentrations of 
Verteporfin were tested (Appendix: Figure 26) with the addition of G1 (Figure 16). The 
inhibitor was shown to be very efficient even in very low doses of the grade of 10nM which 
was chosen as the optimum. 
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Figure 16: Verteporfin (VP) treatment attenuates proliferation capacities of HCT116 cell line. HCT116 cells 
were incubated with VP at various concentrations (250, 100, 50 and 10 nM,) for different durations (24, 48, 72 
hours), respectively with and without the addition of G1 (100nM). Viable cells were analysed using BrdU assay, 




Verteporfin effect on growth was further verified with more proliferation assays with G1 and 
E2 treatment for 48 hours. All results showed a trend towards increase in the proliferation 
rate after E2 treatment and a statistical significant inhibition (p<0.05) in the proliferation rate 
after G1 treatment with addition of Verteporfin (Figure 17).  
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Figure 17: Verteporfin blocked GPER-driven cell proliferation in HCT116 cells. Cells were treated with E2 
(100nM) and G1 (100nM) for 48 hours with and without the addition of Verteporfin (10 nM). Viable cells were 
analyzed using BrdU assay, whose results are expressed as absortion in 405nm. All conditions are normalised to 
the dFBS control without cells. 2-tailed Student’s t test showed significantly different among G1 treatments 
after Verteporfin addition *p < 0.05.  
 
3.3.4 GPER-induced cell proliferation was blocked by YAP1 transient knockdown in 
HCT116 cells. 
 
We next silenced YAP1 in HCT116 with the use of siRNA. The efficiency of the knockdown 
was very high since the mRNA and protein levels were almost diminished, compared to the 
untreated control, from the first 24 hours after transfection (Figure 18). 
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 Figure 18: YAP1 siRNA optimization in HCT116 cells. mRNA and protein was collected 24, 48, 72 and 96 
hours after transfection. The relative YAP1 expression was diminished after 24 hour of transfection and the 
silencing was stable for up to 96 hours. Cell lysates from HCT116 cells, 24, 48, 72 and 96 hours after 
transfection, were resolved by 10% SDS–PAGE with B-actin as the loading control.  YAP1 (75 kDa) protein 
expression was highly decreased for the first 24 hours and the knockdown was stable for up to 96 hours. 
 
To further delineate YAP1 action in CRC, we employed proliferation assays with the YAP1 
knockdown cells and non-target siRNA transfected cells as control (Figure 19). The results in 
figure 19 suggested that HCT116 YAP1 knockdown cells loss their ability to respond to the 
proliferative effect of E2 treatment (as shown in Figure 9). Furthermore, G1 effect in YAP1 
knockdown cells was cytotoxic compare to the no target control suggesting clearly that 
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Figure 19: GPER promotes cell proliferation through YAP1. HCT116 expressing YAP1 and HCT116 YAP1 
knockdowns were treated with E2 (100nM) and G1 (100nM) for 48 hours. Viable cells were analysed using 
BrdU assay, whose results are expressed as absorption in 405nm. All conditions are normalised to the dFBS 
control without cells. YAP1 knockdown HCT116 cells do not respond to E2 and G1 treatment. Compared to the 
non-targeting negative control G1 is shown to be cytotoxic for the YAP1 knockdown cells 2-tailed Student’s t 
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4. Discussion 
 
Colorectal cancer is the third most commonly diagnosed cancer in both sexes and the second 
cause of cancer-related death in Europe 2. Here we investigated whether oestrogens effect 
CRC proliferation via GPER and Hippo Pathway signalling.  
 
In CRC the research in oestrogen induced action through GPER is limited and controversial. 
Liu and colleagues study shows that GPER mRNA and protein expression is downregulated 
in CRC compared to matched normal tissue and this downregulation is associated with poorer 
prognosis 100. Published data from our lab support the fact that GPER mRNA levels are 
decreased in human CRC tissue compared to matched normal tissue. However, GPER protein 
levels were reported to be raised in human CRC tissue compared to matched normal control 
implying that GPER protein degradation pathways possibly alter in CRC, permitting GPER 
protein retention 37.   
 
Liu and colleagues study also proposed that GPER stimulation by G1 leads to G2/M phase 
arrest, elevated ER stress, and increased apoptosis in CRC cells via the Ras/ERK1/2 and 
NFκB pathway 100. However, our results here demonstrate that ER negative but GPER 
positive HCT116 present increased proliferation rate after E2 and G1 treatment with the 
effect inhibited by 35% after use of the specific GPER antagonist G15. The contrast to our 
findings is possible due to use of different experimental conditions. In detail, Liu and 
colleagues employed in their experiments doses of G1 up to 10 µM where we used 100 nM. 
Interestingly, previous projects in our lab have proven this biphasic response to G1 where 
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low doses increase the proliferation rate of CRC cells and high doses induce apoptosis, alike 
ERα biphasic stimulation in breast cancer cells  37,101. 
 
Santolla and colleagues propose that GPER stimulation by E2 is associated with increased 
proliferation in Lovo cells via a FASN-mediated mechanism102. Taking into consideration 
that the GPER-FASN mechanism was common in colon and breast cancer we decided to 
examine if known signalling pathways of GPER in breast apply to CRC. Pandey and 
colleagues examined the expression profiling of GPER signalling in ERα and ERβ negative 
SKBr3 breast cancer cells. They identified CTGF as the  gene most induced by E2 and OHT 
81. Thus, we examined CTGF gene expression levels in HCT116, HT29 and CACO2 CRC 
cells after E2 and G1 treatment. The results showed no significant alteration in CTGF gene 
expression levels (Figure 10). However, previous experiments in our lab had evidenced that 
GPER stimulation after E2 and G1 (100nM) treatment leads to CTGF upregulation and 
elevated protein expression in HCT116 and HT29 cells 37. The controversy between the 
results may be due to different passage number of the cells examined.     
 
One of the hallmarks of cancer is silencing of tumour suppressor genes and pathways. 
Previous studies have demonstrated that aberrant modifications in the key components of the 
Hippo pathway may be associated with increased proliferation and possible carcinogenesis 
84,92,103. The Hippo pathway has been reported to be cross talked with many well-known 
signaling pathways in malignancy. Previous data shows that in skin cancer YAP/TAZ are 
associated with  TGFβ signalling pathway (SMAD2/3) 104. In colon cancer, Hippo signalling 
and Akt pathway has been reported to interact and control cell growth 105 and YAP/TAZ have 
been suggested to mediate GPCR proliferative effects in intestinal epithelial cells through the 
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PKD gene family 106. In breast, prostate and colon cancerous cells inhibition of ILK resulted 
in regulation of MST1 and LATS1 followed by YAP/TAZ inactivation 107.  
 
Hormones have been implicated in the Hippo pathway in the evolutional study of Yu and 
colleagues in which a large amount of GPCR ligands where tested for possible association 
with YAP/TAZ action, such as ERα and thyroid stimulating hormone receptor 95. In a more 
recent study of Zhou and colleagues, treatment with E2, OHT and G1 induced rapid and 
significant YAP1 dephosphorylation and TAZ accumulation in different breast cancer cells. 
The responses were blocked with GPERs antagonist G15 and with GPER knockdown, 
suggesting a cell line–independent roles of GPER in YAP/TAZ activation 96.                    
                              
To examine whether GPER is associated with the Hippo pathway in CRC, we treated CRC 
cells in stripped media with E2, G1 and G15. Immunoblotting (figure 11-13) and 
Immunostaining (figure 14) revealed rapid increase in YAP1’s phosphorylation, with G15 to 
attenuate YAP1 nuclear-cytoplasmic shuttling, in HCT116 cells. HT29 and adenoma cells did 
not respond to treatment. In contrast with the study of Yuen and colleagues, in which TAZ 
mRNA expression is suggested as a prognostic indicator for colon cancer progression, we 
witnessed no change to total TAZ protein levels after oestrogenic treatment in any of the cell 
lines examined 108.   
 
 In normal tissue this early metabolic impact (rapid increase in YAP1’s phosphorylation) 
would be translated into impaired cellular proliferation. However, pharmacological inhibition 
and gene silencing revealed that YAP1 has a pro-proliferative role in HCT116 cells 
suggesting that in malignancy the well elucidated pathway is dysregulated in favour of the 
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neoplasia. In addition to that the differences between the cell lines can be explained by the 
fact that HCT116 cells are highly aggressive and non-differentiating cells in contrast to the 
HT29 which retain some capacity to differentiate 109.  
 
According to literature HCT116 YAP1 and TAZ knockdowns have been demonstrated to 
reduce proliferation independently and synergistic 93. The cytoplasmic YAP1 expression is 
suggested to be significantly higher in colon adenocarcinoma, compared to normal tissues 
and YAP1 has been reported to be upregulated and mounted in the cytoplasm (P-YAP1) 85. 
Taking into consideration that rarely cytoplasmic expression occurs without nuclear 
expression, the inactive P-YAP1 can possible act as a constant reservoir available when 
needed to be dephosphorylated and translocated into the nucleus 85. Furthermore, recent 
evidence points out that mitogenic GPCR stimulation in intestinal epithelia cells, can possible 
be associated with biphasic regulation of YAP1 and rapid cytoplasmic-nuclear shuttling 106. 
The alteration of YAP1 expression in CRC is of great interest as a therapeutic approach, 
considering the role it displays in normal colonic tissue unlike the Wnt and Notch pathways 
whose outputs are fundamental for normal intestinal homeostasis 88.    
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5. Conclusions  
 
Taken together, our results propose a new oestrogen-driven pro-proliferative GPER-




Figure 20: CRC cells internalise E1S and E2S via the OATP4A1 transporter. Intracellularly STS hydrolyses the 
conjugates to their active forms. GPER shuttles between the membrane and the endoplasmic reticulum where 
it’s stimulated by the high affinity E2 and its agonist G1. The receptor activation leads to phosphorylation of 
YAP1, translocation from the nucleus to the cytoplasm and is associated to increase proliferation via an 
mechanism which is yet to be elucidated. 
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6. Futures Aims 
 
This project aim was to provide a basic assessment of the potential role of GPER as 
oestrogen-induced mediator in CRC via the Hippo signalling pathway. Taking into 
consideration the limited duration of the project, all the experiments were performed in 
human immortalised cell lines. However, to verify the physiological relevance of the results 
the experiments should be repeated with the use of CRC and match normal primary cells. 
Furthermore, TAZ and YAP1 gene expression levels would be interesting to be measured in 
paired cancerous and normal human tissue samples, to investigate a possible association 
between YAP1 expression and survival outcome 110. 
 
For our proliferation studies we employed the widely used BrdU incorporation assay which 
measures DNA replication. However, our results between experiments had variations which 
might be overcomed by the use of another cell viability assay, such as MTT that evaluates the 
number of the living cells based on their ability to metabolise MTT into formazan 111. In the 
same time, it would be very interesting to evaluate the apoptosis and cytotoxicity in the cells 
after our oestrogenic treatment with the use of Caspase 3 assay and lactate dehydrogenase 
(LHD) assay respectively 111,112. 
 
The extent of our imaging studies in this project was limited. Due to lack of time live cell 
imaging after oestrogen treatment was not attempted. In a future project it would be very 
interesting to use confocal time series application in order to record GFP-tagged YAP1 
shuttling from the nucleus, where it has been reported to be mainly localised in CRC cell 
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lines 113, to the cytoplasm after oestrogen treatment with the use of G15 and verteporfin. 
However, the use of a GFP-tag can influence localisation and the experimental set up can be 
very challenging. The controversy regarding GPER localisation was promptly investigated 
GPER (Appendix: Figure 24). Immunostaining showed GPER localisation both in the 
membrane and in the cytoplasm of CACO2 cells. Nevertheless, further studies have to be 
done in order to clarify the receptors location and possible shuttling between the membrane 
and the endoplasmic reticulum 79. 
 
The siRNA against YAP1 was very efficient but the non-target siRNA used as control had off 
target effects when treated with oestrogens. The transfection reagent did not appear to have 
off target effects (Appendix: Figure 28). CRC cells were also transfected with siRNA against 
GPER (Appendix: Figure 30) and CTGF (Appendix: Figure 31). The transient knockdown of 
GPER was not efficient and CTGF’s was controversial. This points out on the one hand that 
the experiments should be repeated with an alternative non-target siRNA and on the other 
hand that stable knockdown cell line would be the appropriate tool in order to fully 
investigate the role of YAP1 as well as GPER and possible CTFG. Also, stable GPER and 
YAP1 knockdowns in vivo would elucidate the non-genomic action of GPER and the Hippo 
signaling pathway as well 96.  
 
Further studies are finally required to reveal the detailed signalling cascade by which GPER 
mediates the increased YAP1 phosphorylation. LATS1/2 and MIST1/2 should be the next 
proteins whose phosphorylation and thus action should be investigated with immunoblotting 
after oestrogen treatment. MIST1/2 anti-proliferative effect in normal colon tissue has been 
reported to be suppressed by YAP1 overexpression in CRC 114, consequently it would be very 
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important to examine whether the increased phosphorylation of YAP1 we reported is 
regulated by deactivation of these modulator and investigate the unclear role of LATS1/2. 
Furthermore, it would be very interesting to examine TEAD activation upon oestrogen 
treatment and GPER inhibition with Luciferase-based genetic reporter assays and investigate 
the role of Gαq/11 and PLCβ/PKC in the upregulation of YAP1 via GPER  which has been 
reported in breast cancer to be of paramount importance 96. 
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7. Appendix 
 
Table 10: Western blot buffers and their components 
TBS-T 1X 
1M TRIS pH 7,6 50 ml 
NACI 20 g 
Tween80 0.625 ml 
dWater 2447 ml 
 
  
Transfer Buffer 1X 
MEOH 400 ml 
Glycine 28.8 g 
TRISMA BASE 6 g 
dWater 1600 ml 
 
Running Buffer 1X 
10x Tris/Glycine/SDS 100 ml 
dWater 900 ml 
 
Mild stripping 
Glycine 15 g 
SDS 1 g 
Tween20/80 10/2.5ml 
              Adjust pH to 2.2. Bring volume up to 1 L with ultrapure water 
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Figure 21:  Full blots of ERα (66 kDa), ERβ (59 kDa), GPER (38 kDa) in human colon adenoma and 
adenocarcinoma cell lines. Cell lysates from  AA/C1, RG/C2, CACO2, HT29 and HCT116 cells were resolved 
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Figure 22: CTGF is expressed in CRC cell lines. qRT-PCR was performed in untreated human CRC cell lines 
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Figure 23: YAP1 is expressed in CRC cell lines. qRT-PCR and Immunodetection was performed in untreated 
human CRC cell lines CACO2, HT29 and HCT116. Various concentrations of cell lysates were resolved by 
10% SDS–PAGE with B-actin as the loading control. The results suggested that the optimal concentration was 
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Figure 24: Immunocytochemistry of GPER (red) in human cancer colon cell line. CACO2 cells were stained 
and the Nuclear DNA labelling (blue) was done with Hoechst 33342. GPER is reported to be localised on the 
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Figure 25: Immunocytochemistry of YAP (green) in human cancer colon cell line. HCT116 cells were stained 
and the Nuclear DNA labelling (blue) was done with Hoechst 33342. The inhibition of action is clean with the 
use of G15. Oestrogens (E2) appear to phosphorylate YAP and the dephosphorylated form is appear to be 
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Figure 26: Immunocytochemistry of YAP (green) in human cancer colon cell line. HCT116 cells were stained 
and the Nuclear DNA labelling (blue) was done with Hoechst 33342. The inhibition of action is clean with the 
use of G15. G1 appears to phosphorylate YAP  and the dephosphorylated form is appear to be increased after 
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Figure 27: (VP) treatment attenuates proliferation capacities of HCT116 cell line. HCT116 cells were incubated 
with VP at various concentrations (2.5, 5, 10, and 20 μM) for different durations (24, 48, 72 hours), respectively 
with and without the addition of G1 (100nM). Viable cells were analysed using BrdU assay, whose results are 
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Figure 28: HCT116 incubated with non-target siRNA and HCT116 cell incubated with the transfection reagent 
Dharmafect 4 were treated with E2 (100nM) and G1 (100nM) for 48 hours. Viable cells were analysed using 
BrdU assay, whose results are expressed as absorption in 405nm. All conditions are normalised to the dFBS 
control without cells. HCT116 cell incubated with the transfection reagent Dharmafect have a trend towards 
increase in proliferation after E2 and G1 treatment. HCT116 incubated with non-target siRNA do not respond to 
treatment. 2-tailed Student’s t test showed significantly different among G1 treatments after Verteporfin 
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Figure 29: HCT116 incubated with non-target siRNA and HCT116 cell grown in double stripped media were 
treated with E2 (100nM) and G1 (100nM) for 48 hours. Viable cells were analysed using BrdU assay, whose 
results are expressed as absorption in 405nm. All conditions are normalised to the dFBS control without cells. 
HCT116 cell grown in double stripped media have a trend towards increase in proliferation after E2 and G1 
treatment. HCT116 incubated with non-target siRNA do not respond to treatment. 2-tailed Student’s t test 
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Figure 30: GPER siRNA optimization in HCT116 cells. Cells were transfected with 25nM of siRNA. After 24 
hours the stripped media was replaced with fresh double stripped media. mRNA and protein was collected 24, 
48, 72 and 96 hours after transfection. Cell lysates from HCT116 cells, 24, 48, 72 and 96 hours after 
transfection, were resolved by 10% SDS–PAGE with B-actin as the loading control.  GPER (38 kDa) protein 
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Figure 31: CTGF siRNA optimization in HCT116 cells. Cells were transfected with 25nM of siRNA. After 24 
hours the stripped media was replaced with fresh double stripped media. mRNA and protein was collected 24, 
48, 72 and 96 hours after transfection. Cell lysates from HCT116 cells, 24, 48, 72 and 96 hours after 
transfection, were resolved by 10% SDS–PAGE with B-actin as the loading control.  CTGF (38 kDa) protein 
expression was reduced after 72 hour of transfection 
